These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36923235)

  • 1. Utility of Polygenic Risk Scoring to Predict Cognitive Impairment as Measured by Preclinical Alzheimer Cognitive Composite Score.
    Gao Q; Daunt P; Gibson AM; Pither RJ;
    JAR Life; 2022; 11():1-8. PubMed ID: 36923235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic Risk Scoring is an Effective Approach to Predict Those Individuals Most Likely to Decline Cognitively Due to Alzheimer's Disease.
    Daunt P; Ballard CG; Creese B; Davidson G; Hardy J; Oshota O; Pither RJ; Gibson AM
    J Prev Alzheimers Dis; 2021; 8(1):78-83. PubMed ID: 33336228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
    Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
    BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.
    Donohue MC; Sperling RA; Salmon DP; Rentz DM; Raman R; Thomas RG; Weiner M; Aisen PS; ; ;
    JAMA Neurol; 2014 Aug; 71(8):961-70. PubMed ID: 24886908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.
    Porter T; Burnham SC; Savage G; Lim YY; Maruff P; Milicic L; Peretti M; Ames D; Masters CL; Martins RN; Rainey-Smith S; Rowe CC; Salvado O; Taddei K; Groth D; Verdile G; Villemagne VL; Laws SM
    Front Aging Neurosci; 2018; 10():423. PubMed ID: 30620773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.
    Bransby L; Lim YY; Ames D; Fowler C; Roberston J; Harrington K; Snyder PJ; Villemagne VL; Salvado O; Masters CL; Maruff P
    J Clin Exp Neuropsychol; 2019 Aug; 41(6):591-600. PubMed ID: 30924399
    [No Abstract]   [Full Text] [Related]  

  • 8. Polygenic Risk Score Analysis of Alzheimer's Disease in Cases without APOE4 or APOE2 Alleles.
    Escott-Price V; Myers A; Huentelman M; Shoai M; Hardy J
    J Prev Alzheimers Dis; 2019; 6(1):16-19. PubMed ID: 30569081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of polygenic risk for Alzheimer's disease on rate of cognitive decline in normal aging.
    Kauppi K; Rönnlund M; Nordin Adolfsson A; Pudas S; Adolfsson R
    Transl Psychiatry; 2020 Jul; 10(1):250. PubMed ID: 32709845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polygenic coronary artery disease association with brain atrophy in the cognitively impaired.
    de Silva E; Sudre CH; Barnes J; Scelsi MA; Altmann A;
    Brain Commun; 2022; 4(6):fcac314. PubMed ID: 36523268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An interpretable Alzheimer's disease oligogenic risk score informed by neuroimaging biomarkers improves risk prediction and stratification.
    Suh EH; Lee G; Jung SH; Wen Z; Bao J; Nho K; Huang H; Davatzikos C; Saykin AJ; Thompson PM; Shen L; Kim D;
    Front Aging Neurosci; 2023; 15():1281748. PubMed ID: 37953885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies.
    Sato K; Mano T; Ihara R; Suzuki K; Niimi Y; Toda T; Iwatsubo T; Iwata A
    J Prev Alzheimers Dis; 2021; 8(4):503-512. PubMed ID: 34585226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond
    Altmann A; Scelsi MA; Shoai M; de Silva E; Aksman LM; Cash DM; Hardy J; Schott JM
    Brain Commun; 2020; 2(1):fcz047. PubMed ID: 32226939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive Decline in Alzheimer's Disease: Limited Clinical Utility for GWAS or Polygenic Risk Scores in a Clinical Trial Setting.
    Euesden J; Gowrisankar S; Qu AX; Jean PS; Hughes AR; Pulford DJ
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32370229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.